

7th Annual Brain Metastases Research and Emerging Therapy Conference

**October 6-7, 2017
Marseille, France**

Program Chairs

M. Ahluwalia (US)
E. Le Rhun (FR)
P. Métellus (FR)
M. Weller (CH)

Scientific Committee

M. Ahluwalia (US)
F. Dhermain (FR)
E. Le Rhun (FR)
P. Métellus (FR)
Z. Ram (IL)
R. Soffietti (IT)
M. Weller (CH)
M. Westphal (DE)





www.globals.fr

Tel : +33 (0)4 82 53 22 60

7th Annual
Brain Metastases
Research and
Emerging
Therapy
Conference
October 6-7, 2017
Marseille, France

Welcome Letter

We are pleased to welcome you to Marseille for the seventh Annual Brain Metastases Research and Emerging Therapy Conference. Last year's successful edition encouraged us to once again organize this conference.

This year the meeting will be held under the auspices of EORTC, EANO and EANS. Also the French neuro-oncology group (ANOCEF) and the French society of neuro-surgery are partners of this event. This initiative brings the multidisciplinary approach needed to develop Brain Metastases projects across several tumor types and disciplines such as breast cancer, lung cancer, melanoma, imaging, radiation oncology, pathology and molecular. It is expected that this cross-sectional meeting will stimulate innovative and insightful research in a collaborative environment and improve the standard of care and methodology of clinical research.

For this 7th edition, a special session will be dedicated to Immuno-oncology in CNS Metastases. Actually, cancer immunotherapy clinical trials are critical to bringing new and potentially lifesaving treatments to more patients with more types of cancer, and may represent the greatest hope especially for patients currently facing Brain Metastases. Highlighted topics will also cover adverse radiation effect in the era of targeted therapies, new pharmacological approaches and combined treatments in BM.

One of the objectives of this edition will be to describe the clinical problem, identify the critical points of therapeutic failure and summarize the current state of knowledge of the genetics and biology of Brain Metastases. The overarching goal of the meeting is to generate a set of research priorities that would stimulate integrated scientific and clinical investigation directed at understanding basic processes of brain metastasis and translating such insights to clinical care.

The organizing committee hopes that this meeting will provide an exceptional opportunity for you to share your collective expertise ranging from basic science to new treatments in order to facilitate ongoing studies and lay the foundation for future collaborative projects.

PROGRAM CHAIRS:

Manmeet Ahluwalia, Emilie Le Rhun, Philippe Métellus & Michael Weller

Friday October 6th

08.30 Welcome coffee

08.45 Welcome address, *Philippe Métellus (France)*

09.00 Diagnostic approaches

*Chairs: Antoine Carpentier (France)
& Marion Smits (The Netherlands)*

- 09.00 Molecular profiling to allocate patients to targeted clinical trials, *Johan M. Kros (The Netherlands)*
- 09.20 Surgical perspectives in Brain Metastases, *Manfred Westphal (Germany)*
- 09.40 Leptomeningeal Metastases, *Emilie Le Rhun (France)*

10.00 Immuno-oncology in CNS Metastases

*Chairs: Anna Sophie Berghoff (Austria)
& Frédéric Dhermain (France)*

- 10.00 Lessons from animal models, *Manuel Valiente (Spain)*
- 10.20 Overview: immunotherapy in CNS Metastases, *Manmeet Ahluwalia (USA)*
- 10.40 Toxicity of immunotherapy in CNS Metastases, *Antoine Carpentier (France)*

11.00 Coffee break and visit of the exhibition

11.20 Combined treatments for CNS Metastases

*Chairs: Elizabeth Moyal (France)
& Zvi Ram (Israel)*

- 11.20 Combination of immunotherapy (IT) and radiotherapy (RT) in CNS Metastases, *Frédéric Dhermain (France)*
- 11.40 Brain Metastases: combination of immunotherapy and other systemic pharmacotherapy, *Gaetano Finocchiaro (Italy)*
- 12.00 Combination of other systemic pharmacotherapy and radiotherapy, *Ulrich Herrlinger (Germany)*

12.20 Keynote lecture

*Chairs: Antoine Carpentier (France)
& Ulrich Herrlinger (Germany)*

- 12.20 The future of radiotherapy for CNS Metastases: farewell to WBRT? *Anthony Chalmers (United Kingdom)*

12.50 Lunch

13.20 Symposium



Chair: Frédéric Dhermain (France)

Immunotherapy and targeted therapies in NSCLC Brain Metastases: emerging options in precision medicine

- 13.20 EGFR TKIs in Brain Metastases: which best therapeutic course? *David Planchard (France)*
- 13.40 Immuno-oncology & radiotherapy: advances and practical issues in the management of NSCLC Brain Metastases, *Elizabeth Moyal (France)*

14.00 Comprehensive care of patients with Brain Metastases

*Chairs: Gaetano Finocchiaro (Italy)
& Emilie Le Rhun (France)*

- 14.00 Epilepsy in CNS Metastases: primary and secondary prevention, *Roberta Rudà (Italy)*
- 14.20 Maintaining cognitive function in patients with CNS Metastases receiving multimodality treatment, *Jeffrey Scott Wefel (USA)*
- 14.40 Prevention and treatment of cerebro-vascular complications, *Christine Marosi (Austria)*
- 15.00 Efficacy, tolerability and safety of steroids in patients with CNS Metastases, *Patrick Roth (Switzerland)*

15.20 Interactive case reports (progression/criteria of evaluation)

*Chairs: Philippe Métellus (France)
& Michael Weller (Switzerland)*

- 15.20 Case 1 (Syst chemo), *Amélie Darlix (France)*
- 15.30 Case 2: immune checkpoint inhibitors in Brain Metastases, *Anna Sophie Berghoff (Austria)*
- 15.40 Case 3 (RT), *Anouchka Modesto (France)*

15.50 Coffee break and visit of the exhibition

16.20 Keynote lecture

*Chairs: Riccardo Soffietti (Italy)
& Manfred Westphal (Germany)*

- 16.20 Assessing response and clinical benefit in clinical trials enrolling patients with Brain and leptomeningeal Metastases, *Michael Weller (Switzerland)*
- 17.00** Activities of EORTC BTG CNS Metastases Committee, *Emilie Le Rhun (France)*

17.15 Guided poster walks

20.00 Gala dinner



Accreditation statement.
9 European CME credits (ECMEC) by the European Accreditation Council
for Continuing Medical Education (EACCME).

Saturday October 7th

08.00 Welcome coffee

08.30 Selected oral presentations

*Chairs: Anthony Chalmers (United Kingdom)
& Agnès Tallet (France)*

- 08.30 New models for studies on metastatic cascades and therapy efficacy in melanoma Brain Metastases, *Dayana Herrera Rios (Germany)*
- 08.40 The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and Brain Metastases: the implications for BRAF inhibitor therapy, *Enda Hannan (Ireland)*
- 08.50 The role of T lymphocytes in Brain Metastases, *Rute Marisa Santos Moreira Pedrosa (The Netherlands)*
- 09.00 DNA-damage response in CTCs of metastatic breast and lung cancer under radiotherapy indicates treatment response, *Yvonne Goy (Germany)*
- 09.10 Factors influencing 5-ALA fluorescence intensity of cerebral Metastases, *Ivan Khapov (Russia)*
- 09.20 Clinical and radiological response of BRAF- and MEK-inhibition in patients with Brain Metastases from BRAF-mutated melanoma, *Dieta Brandsma (The Netherlands)*
- 09.30 Tolerance and outcomes of stereotactic radiosurgery combined with anti-PD1 (pembrolizumab) for melanoma Brain Metastases, *Charl  e Nardin (France)*
- 09.40 Underweight is a negative prognostic factor for patients with Brain Metastases from lung cancer, but not other primary tumors, *Fabian Wolpert (Switzerland)*

- 09.50 Survival after whole brain radiotherapy for Brain Metastases from lung cancer and breast cancer is poor in 6,325 Dutch patients treated between 2000 and 2014, *Paul Jeene (The Netherlands)*

- 10.00 Entrectinib, an investigational CNS-penetrating TRK-inhibitor, shows anti-tumor activity in primary and metastatic Brain tumors harboring NTRK, ROS1, and ALK gene fusions, *Am  lie Darlix (France)*

10.10 Coffee break and visit of the exhibition

10.30 Highlights 2016-2017

*Chairs: Anthony Chalmers (United Kingdom)
& Colin Watts (United Kingdom)*

- 10.30 Microenvironmental contributions to CNS Metastases, *Adrienne Boire (USA)*
- 10.50 Neuropathology, *Pieter Wesseling (The Netherlands)*
- 11.10 Imaging for Brain Metastases, *Marion Smits (The Netherlands)*
- 11.30 Surgery of Brain Metastases, *Philippe M  tellus (France)*
- 11.50 Radiation therapy, *Elizabeth Moyal (France)*
- 12.10 Perspectives in systemic treatments for BM patients, *Martin J. van den Bent (The Netherlands)*

12.30 Awards – Best communication
and poster – Conclusions

12.45 Lunch

AstraZeneca 

novocureTM

 NOVARTIS

 Daiichi-Sankyo

GlobalS
Solution Implants

SAMSUNG

stryker[®]

MEDICREA[®]
IMPROVE

1^{er} TKI-EGFR
ciblant la mutation
T790M*



PUISSANCE

PRÉCISION



TAGRISSO™ est indiqué dans le traitement des patients adultes atteints d'un cancer bronchique non à petites cellules (CBNPC) localement avancé ou métastatique, avec mutation EGFR T790M (récepteur du facteur de croissance épidermique).

Les études cliniques n'ont pas été conduites chez les patients atteints d'un CBNPC et porteurs de la mutation EGFR T790M de novo ⁽¹⁾. La place de TAGRISSO™ dans la stratégie thérapeutique pour cette population ne peut être définie⁽²⁾. TAGRISSO™ peut représenter un traitement de première intention chez les patients atteints d'un CBNPC localement avancé ou métastatique porteur de la mutation EGFR T790M ayant progressé pendant ou après un traitement par inhibiteur de tyrosine kinase anti EGFR ⁽²⁾.

Non remboursable à la date du 20 avril 2017(demande d'admission à l'étude).

Prise en charge selon les conditions définies à l'article L.162-16-5-2 du Code de la Sécurité Sociale suite à l'ATU accordée du 4 septembre 2015 au 28 avril 2016.

Les mentions légales sont disponibles sur la base de données publique des médicaments (<http://base-donnees-publique.medicaments.gouv.fr>).

▼ Ce médicament fait l'objet d'une surveillance supplémentaire qui permettra l'identification rapide de nouvelles informations relatives à la sécurité.

* AMM européenne en date du 2 février 2016.

(1) Résumé des Caractéristiques du Produit TAGRISSO™.

(2) HAS. Avis de la Commission de la Transparence TAGRISSO™. 21 Septembre 2016.

AstraZeneca